在血清刺激或线粒体退出后,UHRF2在早期G1阶段积累,以延长G1和细胞周期总长度
Xiaohong Wang1, Huarui Lu1, Grace Sprangers1
1Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN, USA.
与PHD和环指域2 (UHRF2) 一样,乌比奎丁通过控制基因表达和蛋白质稳定性来调节细胞循环节奏. 失去UHRF2会延迟细胞循环的进展,并影响循环素和CDK抑制剂水平.
科学领域:
- 细胞生物学 细胞生物学
- 分子生物学分子生物学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 与PHD和戒指域2 (UHRF2) 类似的乌比奎丁与UHRF1同源,但缺乏其DNA甲基化功能.
- 在细胞循环进展中的UHRF2的作用及其致癌或瘤抑制功能尚未完全理解.
- UHRF2与E2F1相互作用,并受到循环E/CDK2的调节,这表明它参与细胞循环控制.
研究的目的:
- 阐明UHRF2在细胞循环调节中的精确作用.
- 研究UHRF2通过哪些机制影响细胞周期基因表达和蛋白质稳定性的机制.
- 为了确定UHRF2调制对细胞周期进展的影响.
主要方法:
- 在CRISPR/Cas9基因编辑中删除UHRF2.2.
- 药理上抑制CDK1以研究UHRF2的动态.
- 细胞周期阶段过渡时间的分析.
- 定量循环素,CDK抑制剂 (例如,p27KIP1) 和视网母细胞瘤酸化水平.
主要成果:
- 在早期G1中观察到UHRF2表达,并在M阶段丢失,由于CDK1抑制,耗尽可逆.
- 使用CRISPR/Cas9删除UHRF2显著延迟了细胞周期的所有阶段的进展.
- 失去UHRF2会导致循环素水平增加和p27KIP1升高,减少视网膜母细胞瘤酸化,并延长G1/S过境.
结论:
- UHRF2 作为细胞周期节奏的关键调节者.
- UHRF2通过复杂的细胞周期基因表达和蛋白质稳定性的调节来控制细胞周期进展.
- UHRF2复杂的相互作用和反循环突出了它在维持细胞周期动态中的核心作用.
更多相关视频
12:02Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols
Published on: June 6, 2017
08:37Use of the Pyrimidine Analog, 5-Iodo-2′-Deoxyuridine IdU with Cell Cycle Markers to Establish Cell Cycle Phases in a Mass Cytometry Platform
Published on: October 22, 2021
相关概念视频
DNA Damage can Stall the Cell Cycle
Negative Regulator Molecules
Positive Regulator Molecules
Molecular Factors Affecting Cell Division
Several proteins function as internal regulators to ensure each cell cycle stage is completed faithfully before proceeding to the next. Regulator molecules may act directly or influence the activity or production of other...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
The Cell Cycle Control System
Cyclins and cyclin-dependent kinases (Cdks) are the primary cell cycle regulators and...
